D-Dimer as a Risk Factor for the Severity of COVID-19 Infection

Dhamya Kadhim Sarhan, Intisar R. Sharba, Zainab Basim Mohammed

Abstract

Background: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has a variable clinical course, and mortality risk factors are not well established. Methods: This retrospective study included adult inpatients (≥20 years old) with laboratory-confirmed COVID-19 from Al-Sadder Hospital and Alamal Hospital in Al-Najaf, Iraq. The patients either died or were discharged between December 1, 2021, and January 31, 2022. Data on demographics, clinical trials, treatments, and laboratory results were collected from the hospital database for both survivors and non-survivors. Statistical analyses were performed to identify the risk factors for in-hospital mortality. Results: A total of 100 patients were included in the study, of whom 67 were discharged and 33 died in the hospital. The age distribution showed that 45% of the patients were under 40 years of age, while 55% were over 40 years old. The cohort comprised 57% males (37 survivors vs. 20 non-survivors, p=0.024) and 43% females (30 survivors vs. 13 non-survivors, p=0.010). Comorbidities were present in 66% of the patients, with 55% of the survivors and 87% of the non-survivors having underlying conditions. Notably, diabetes mellitus was more prevalent in the non-survivors (85% vs. 18%), followed by asthma (58% vs. 10%), stroke (48% vs. 10%), renal failure (42% vs. 6%), heart attack (33% vs. 10%), and hypertension (18% vs. 15%). The findings revealed a median white blood cell (WBC) count of 8.7 mg/dl (IQR: 6.1–15.63 mg/dl), lymphocyte count of 57.6 (52.8–61.1), D-dimer levels of 2.35 μg/ml (IQR: 1.2–4.72 μg/ml), ferritin levels of 775 μg/ml (IQR: 720.3–866.4 μg/ml), C-reactive protein (CRP) levels of 4.55 mg/dl (IQR: 1.5–5.3 mg/dl), and lactate dehydrogenase (LDH) levels of 341.5 IU/L (IQR: 291.3–427 IU/L). These parameters were significantly higher in the non-survivors than in the survivors. A significant positive correlation was found between D-dimer and ferritin, CRP, and LDH as well as between WBC and lymphocyte counts and LDH. ROC analysis indicated that CRP had an area under the curve (AUC) of 0.802 (95% CI: 0.717-0.886) with a cutoff of 4.45 mg/dl, demonstrating 87.9% sensitivity and 37.3% specificity. D-dimer showed an AUC of 0.749 (95% CI: 0.652-0.846) with cutoff of 2.40 μg/ml, 81.8%, and 32.8%, respectively. LDH had an AUC of 0.70 (95% CI: 0.587-0.813) with a cutoff of 353.50 IU/L and 72.7% sensitivity and 37.3% specificity. Ferritin had the lowest AUC of 0.684 (95% CI: 0.555-0.813), with cutoff of 809.50 μg/ml, 69.7%, and 37.1%, respectively. Conclusion: This study found that older age correlates with elevated D-dimer, ferritin, CRP, and LDH levels. These parameters are associated with disease severity and mortality risk in adult COVID-19 patients. D-dimer and CRP levels have emerged as two of the most reliable predictors of disease progression. Understanding the interplay between these biomarkers and disease progression may lead to targeted therapeutic interventions and better resource allocation in healthcare settings.


Keywords: D-dimer, coronavirus disease, ferritin, receiver operating curve (ROC), area under the curve (AUC)


 

Full Text:

PDF


References


GUO, YR, CAO Q. D, HONG ZS, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on the status. Mil Med Res, 2020, 7(1): 11, doi: 10.1186/s40779-020-00240-0

ZHOU M, ZHANG X, & QU J. Coronavirus disease 2019 (COVID-19): a clinical update. Front Med, 2020, 14(2): 126-135, doi: 10.1007/s11684-020-0767-8

POLAK SB, VAN GOOL IC, COHEN D, et al. A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression. Mod. Pathol, 2020, 33(11): 2128–2138, doi: 10.1038/s41379-020-0603-3

LINO K, GUIMARÃES GMC, ALVES LS, et al. Serum ferritin at admission in hospitalized COVID-19 patients as a predictor of mortality. Braz J Infect Dis, 2021, 25(2): 101569, doi: 0.1016/j.bjid.2021.101569

MELO AKG, MILBY KM, CAPARROZ ALM, et al. Biomarkers of cytokine storm as red flags for severe and fatal COVID-19 cases: A living systematic review and meta-analysis. PloS One, 2021, 16(6): e0253894, doi: 10.1371/journal.pone.0253894

POUDEL A, POUDEL Y, ADHIKARI A, et al. D-dimer as a biomarker for assessment of COVID-19 prognosis: D-dimer levels on admission and its role in predicting disease outcome in hospitalized patients with COVID-19. PLoS One, 2021, 16(8): e0256744, doi: 10.1371/journal.pone.0256744

SULLIVAN LM. Essentials of biostatistics in public health. Jones & Bartlett Learning, 2017.

HONG KH, CHOI JP, HONG SH, et al. Predictors of mortality in Middle East respiratory syndrome (MERS). Thorax, 2018, 73(3): 286-289, doi: 10.1136/thoraxjnl-2016-209313

OPAL SM, GIRARD TD, & ELY EW. The immunopathogenesis of sepsis in elderly patients. Clin Infect Dis, 2005, 41(Supplement_7): S504-S512, doi: 10.1086/432007

BOZKURT FT, TERCAN M, PATMANO G, et al. Can ferritin levels predict the severity of illness in patients with COVID-19? Cureus, 2021, 13(1), doi: 10.7759/cureus.12832

LI, B, YANG, J, ZHAO, F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol, 2020, 109(5): 531-538, doi: 10.1007/s00392-020-01626-9

EMAMI A, JAVANMARDI F, PIRBONYEH N, & AKBARI A. Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis. Arch Acad Emerg Med, 2020, 8(1): e35‏

ORIOLI L, HERMANS MP, THISSEN JP, et al. COVID-19 in diabetic patients: Related risks and specifics of management. Ann Endocrinol (Paris), 2020, 81(2-3): 101-109), doi: 10.1016/j.ando.2020.05.001

SINGER M, DEUTSCHMAN CS, SEYMOUR CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). Jama, 2016, 315(8): 801-810, doi: 10.1001/jama.2016.0287

ZHANG X, TAN Y, LING Y, et al. Viral and host factors related to the clinical outcome of COVID-19. Nature, 2020, 583(7816): 437-440, doi: 10.1038/s41586-020-2355-0

XU H, ZHONG L, DENG J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci, 2020, 12(1): 8, doi: 10.1038/s41368-020-0074-x

ZHOU F, WANG Y, LIU Y, et al. Disease severity and clinical outcomes of community-acquired pneumonia caused by non-influenza respiratory viruses in adults: a multicentre prospective registry study from the CAP-China Network. Eur Respir J, 2019, 54(2): 1802406, doi:‏ 10.1183/13993003.02406-2018

NIZAMI DJ, RAMAN V, PAULOSE L, et al. Role of laboratory biomarkers in assessing the severity of COVID-19 disease. A cross-sectional study. J Family Med Prim Care, 2021, 10(6): 2209-2215, doi: 10.4103/jfmpc.jfmpc_145_21

RAHMAN MA, SHANJANA Y, TUSHAR MI, et al. Hematological abnormalities and comorbidities are associated with COVID-19 severity among hospitalized patients: experience from Bangladesh. PLoS One, 2021, 16(7): e0255379, doi: 10.1371/journal.pone.0255379

TANG N, BAI H, CHEN X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J. Thromb Haemost, 2020, 18(5): 1094–1099, doi: 10.1111/jth.14817

HENRY BM, DE OLIVEIRA MHS, BENOIT S, et al. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med, 2020, 58(7): 1021-1028, doi:‏ 10.1515/cclm-2020-0369

SPIEZIA L, BOSCOLO A, POLETTO F, et al. COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. Thromb Haemost, 2020, 120(06): 998-1000, doi: 10.1055/s-0040-1710018

SIEMES C, BERENDES P, VAN DER STRAATEN F, et al. The value of D-Dimer in patients with increased C-reactive protein suspected of pulmonary embolism. Blood, 2009, 114(22): 5056, doi: 10.1182/blood.V114.22.5056.5056

JOSE RJ, & MANUEL A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med, 2020, 8(6): e46-e47, doi: 10.1016/s2213-2600(20)30216-2 ‏

TANERI PE, GÓMEZ-OCHOA SA, LLANAJ E, et al. Anemia and iron metabolism in COVID-19: a systematic review and meta-analysis. Eur J Epidemiol, 2020, 35(8): 763-773, doi: 10.1007/s10654-020-00678-5

SHOENFELD Y. Corona (COVID-19) time musings: our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning. Autoimmun Rev, 2020, 19: 102538, doi: 10.1016/j.autrev.2020.102538

WESSLING-RESNICK M. Crossing the iron gate: why and how transferrin receptors mediate viral entry. Annu Rev Nutr, 2018, 38: 431-458, doi: 10.1146/annurev-nutr-082117-051749

GUAN WJ, NI ZY, HU Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Eng J Med, 2020, 382(18): 1708-1720, doi: 10.1056/nejmoa2002032

WU C, CHEN X, CAI Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med, 2020, 180(7): 934-943, doi: 10.1001/jamainternmed.2020.0994 ‏

SHI S, QIN M, SHEN B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol, 2020, 5(7): 802-810, doi: 10.1001/jamacardio.2020.0950 ‏


Refbacks

  • There are currently no refbacks.